Serum Levels of 25-Hydroxyvitamin D and the CYP3A Biomarker 4β-Hydroxycholesterol in a High-Dose Vitamin D Supplementation Study

2013 ◽  
Vol 41 (4) ◽  
pp. 704-708 ◽  
Author(s):  
Linda Björkhem-Bergman ◽  
Hanna Nylén ◽  
Anna-Carin Norlin ◽  
Jonatan D. Lindh ◽  
Lena Ekström ◽  
...  
Keyword(s):  
Vitamin D ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
High Dose Vitamin

VITAMIN D SUPPLEMENTATION IN FEMALE NURSES: THE EFFECTS ON SERUM 25-HYDROXYVITAMIN D, AND NON-SPECIFIC MUSCULOSKELETAL PAIN

2015 ◽  
Vol 18 (02) ◽  
pp. 1550008 ◽  
Author(s):  
Negin Masoudi Alavi ◽  
Mahla Madani ◽  
Mohsen Taghizadeh ◽  
Mohammad Reza Sharif
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Musculoskeletal Pain ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Single High Dose ◽  
Hydroxyvitamin D ◽  
Before And After ◽  
25 Hydroxyvitamin D ◽  
Female Nurses

Purpose: To investigate the effect of weekly single high dose vitamin D supplementation on serum 25-hydroxyvitamin D [25(OH)D], and non-specific musculoskeletal pain in female nurses. Methods: In this prospective study in Kashan/Iran, from April 1, 2014, through September 30, 2014, the 150 nurses with vitamin D deficiency received the weekly pearls of 50,000 units of vitamin D3 for 10 weeks. The serum level of 25(OH)D was measured before and after supplement therapy. The subjects were also asked to complete the Extended Nordic Musculoskeletal Questionnaire. All analyses were conducted with SPSS version 16. Results: After 10 weeks of intervention there was [Formula: see text][Formula: see text]ng/mL increase in 25(OH)D. The 82 nurses (54.7%) had 25(OH)D in normal range, while the 68 nurses (45.3%) were still vitamin D deficient. Weight could explain 15.4% increase in 25(OH)D. Before intervention 135 (90%), of nurses reported musculoskeletal pain in at least one region, after intervention this number decreased to 72.7%. There was a statistically significant improvement in musculoskeletal pain in neck, shoulders, upper back, lower back, hips/tights, knees, and ankles/feet after intervention. Conclusions: The weekly single high dose of vitamin D for 10 weeks could resolve vitamin D deficiency in about half of the patients. Patients with non-specific musculoskeletal pain might benefit from vitamin D supplementation.

25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis

2005 ◽  
Vol 11 (3) ◽  
pp. 266-271 ◽  
Author(s):  
M Soilu-Hänninen ◽  
L Airas ◽  
I Mononen ◽  
A Heikkilä ◽  
M Viljanen ◽  
...  
Keyword(s):  
Vitamin D ◽  
Bone Metabolism ◽  
Sun Exposure ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Hydroxyvitamin D ◽  
Normal Bone ◽  
Vitamin D Levels ◽  
25 Hydroxyvitamin D ◽  
Lower Vitamin

Past sun exposure and vitamin D supplementation have been associated with a reduction in the risk of MS. We measured the serum concentration of 25-hydroxyvitamin D (25[OH]D) at the time of MS diagnosis in 40 MS patients and 40 controls. We found no difference in the serum levels of 25(OH)D between MS patients and controls when all samples or samples obtained during winter months were compared, but MS patients had significantly lower serum 25(OH)D concentrations in June to September than the controls. The vitamin D stores were adequate for bone metabolism (> 37 nmol/L) in 70% of MS patients throughout the year and within the hypovitaminosis level (< 37 nmol/L) in 30% of MS patients at some time of the year. During MS-relapses, 25(OH)D levels were lower than in remission, but mostly within the reference range observed in relation with normal bone metabolism. We conclude that the vitamin D stores in most MS patients are adequate for their normal bone metabolism. However, lower vitamin D levels during MS relapses than in remission suggest that vitamin D could be involved in the regulation of the clinical disease activity of MS. The optimal serum levels of vitamin D for the regulation of immune responses remain to be determined.

scholarly journals Vitamin D Supplementation in Tuberculosis Patients: A Cross Sectional Study

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Dina Keumala Sari ◽  
Nurfida Khairina Arrasyid ◽  
Y. S. Harahap
Keyword(s):  
Vitamin D ◽  
Serum Level ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
Vitamin D Supplementation ◽  
Sectional Study ◽  
Cross Sectional ◽  
Tuberculosis Patients ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

Previous studies have not been able to show with certainty the effect of vitamin D supplementation in tuberculosis patients. The objective of this study is to determine whether vitamin D supplementation to patients with tuberculosis could influence 25-hydroxyvitamin D (25(OH)D) and calcium serum levels. The results, after 28 days, the vitamin D supplementation showed significant increase of 25(OH)D serum level at the end point (p=0.001), but not for the calcium serum level (p=0.3). The Conclusions is supplementation with 1,000 IU vitamin D per day increased the 25(OH)D serum level but there was no association with the calcium serum level.

scholarly journals Peripheral Neuropathy and Hypovitaminosis D Are Associated in Multiple Myeloma Patients

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5506-5506
Author(s):  
Berdien Oortgiesen ◽  
Hans Kroes ◽  
Petra Scholtens ◽  
Jitske Hoogland ◽  
Pauline Dannenberg-de Keijzer ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Vitamin D ◽  
Peripheral Neuropathy ◽  
Hypovitaminosis D ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Hydroxyvitamin D ◽  
Number Of Patients ◽  
Vitamin D Levels ◽  
25 Hydroxyvitamin D

Introduction New strategies in the treatment of multiple myeloma (MM) have improved response rates, progression-free survival and overall survival (OS). Despite the advances in treatment, patients frequently experience adverse events such as chemotherapy-induced peripheral neuropathy (CIPN). CIPN decreases quality of life, and requires dose adjustment, delay or premature termination of treatment, resulting in a negative influence on time to progression and survival. In addition, several studies have found that up to 54% of MM patients have peripheral neuropathy (PN) at diagnosis. A possible mechanism of vitamin D deficiency and PN was found in animal trials, where an increase of nerve growth factor was observed in diabetic rats after supplementation of vitamin D. Furthermore, correction of hypovitaminosis D through vitamin D supplementation was found to reduce PN in patients with DM type 2. Objectives The primary objective of this study was to determine the correlation between the 25-hydroxyvitamin D serum levels and PN in patients with smoldering or symptomatic MM. Secondary objectives were to gain insight into the number of patients with inadequate 25-hydroxyvitamin D serum levels (< 75 nmol/L); to evaluate the influence of different vitamin D levels on the severity of CIPN; to determine the correspondence of the ICPNQ results and patients' records; and to search for differences in prevalence of CIPN for each drug. Methods In this multicentre study, performed in the Medical Center Leeuwarden and Deventer Hospital in the Netherlands, smoldering and symptomatic MM patients were included in the study, regardless of stage or previous treatment. Patients had to be older than 18 years, and able to give informed consent. Blood samples were collected to determine vitamin D levels, and hypovitaminosis D was defined as a 25-hydroxyvitamin D level (vitamin D) below 75 nmol/L. The Indication for Common Toxicity Criteria (CTC) Grading Peripheral Neuropathy Questionnaire (ICPNQ), a validated questionnaire to distinguish different PN grades in MM patients, was used to determine the severity of PN. Visual Analog Scale (VAS) scores were used to grade the intensity of PN. Results We included 120 MM patients with a median age of 68 years (min-max; 48-84), and 57,5% were male. The median vitamin D level was 49.5 nmol/L (min-max; 10-138), and 84% had a serum 25-hydroxyvitamin D level <75 nmol/L. The percentage of patients with PN grade 1 or higher was 69%. In the medical records, absence or presence of PN was mentioned in 40% of the patients by clinicians. The percentage of patients with PN categorized in the vitamin D groups <25, 25-49.9, 50-74.9, and ≥75 nmol/L, was 88, 72, 54, and 79%, respectively. However, patients in the vitamin D group ≥75 nmol/L were diagnosed with MM for a shorter period of time, and received more intensive treatment. A trend was found between lower vitamin D levels (grouped <25, 25-49.9, 50-74.9, and ≥75 nmol/L) and higher incidence of PN (p = 0.036). Conclusions PN and hypovitaminosis D are common in MM patients, and low vitamin D levels are possibly associated with the occurrence of PN. In addition, more attention for PN is needed, as PN is underreported by clinicians. Further research is necessary to clarify the relationship between vitamin D and PN, and whether vitamin D supplementation could positively influence PN in MM patients. Disclosures No relevant conflicts of interest to declare.

scholarly journals Total Duration of Breastfeeding, Vitamin D Supplementation, and Serum Levels of 25-Hydroxyvitamin D

2016 ◽  
Vol 106 (4) ◽  
pp. 714-719 ◽  
Author(s):  
Denise Darmawikarta ◽  
Yang Chen ◽  
Gerald Lebovic ◽  
Catherine S. Birken ◽  
Patricia C. Parkin ◽  
...  
Keyword(s):  
Vitamin D ◽  
Total Duration ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Duration Of Breastfeeding

High-Dose Intramuscular Vitamin D Provides Long-Lasting Moderate Increases in Serum 25-Hydroxvitamin D Levels and Shorter-Term Changes in Plasma Calcium

2017 ◽  
Vol 100 (5) ◽  
pp. 1337-1344 ◽  
Author(s):  
Shelley Gorman ◽  
Mark Zafir ◽  
Ee Mun Lim ◽  
Michael W Clarke ◽  
Gursimran Dhamrait ◽  
...  
Keyword(s):  
Vitamin D ◽  
Serum Levels ◽  
High Dose ◽  
Vitamin D Metabolites ◽  
Institute Of Medicine ◽  
Dihydroxyvitamin D3 ◽  
Hydroxyvitamin D ◽  
Best Management ◽  
25 Hydroxyvitamin D ◽  
Serum Ionized Calcium

Abstract The best management of vitamin D deficiency, defined as a 25-hydroxyvitamin D [(25(OH)D] level &lt;50nM, is unclear. Intramuscular (IM) injection of a large bolus of vitamin D (≥100 000 IU) is used,but its safety is uncertain. In 10 adults given an IM injection of 600 000IU vitamin D3, we measured at baseline and at 1, 2, 3, and 4 weeks postinjection the serum levels of vitamin D3,25(OH)D3, 25(OH)D2, total 25(OH)D, 3-epi-25(OH)D3, and 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] using a standardized LC with tandem MS (MS/MS)assay; serum levels of 25(OH)D using the Abbott ARCHITECT i2000 immunoassay; and markers of bone metabolism. Bone markers and 25(OH)D (immunoassay) were remeasured at 24 weeks. All participants had baseline total 25(OH)D levels &gt;50 nM. Serum 25(OH)D levels increased at 3, 4, and 24 weeks postinjection, peaking at 4 weeks [mean ± SEM of 126 ± 7.9nM (immunoassay) and 100 ± 5.5 nM (LC-MS/MS)]but generally remained &lt;125 nM, the upper limit recommended by the U.S. Institute of Medicine. Serum 24,25(OH)2D3 levels increased at 3 and 4 weeks postinjection. Serum ionized calcium levels were higher than baseline at 1, 3, and 4 weeks postinjection but remained within the clinicallynormal range. Other biochemical parameters, including other vitamin D metabolites, plasma alkaline phosphatase, and parathyroid hormone levels, were unchanged. IM injection of a large bolus of vitamin D effectively increases serum 25(OH)D levels without evidence of metabolic abnormality.

Sign in / Sign up

Export Citation Format

Share Document